# Premature termination of DNA Damage Repair by 3-Methyladenine potentiates cisplatin cytotoxicity in nasopharyngeal carcinoma cells

## TL;DR

3-Methyladenine enhances the effectiveness of cisplatin in killing nasopharyngeal carcinoma cells by interfering with DNA repair.

## Contribution

This study reveals a novel role of 3-MA in potentiating cisplatin's cytotoxicity by inhibiting DNA damage repair in NPC cells.

## Key findings

- Combining 3-MA with cisplatin significantly reduced cell viability and lowered the IC50 in NPC cells.
- 3-MA enhanced apoptosis and mitochondrial membrane potential loss when combined with cisplatin.
- 3-MA suppressed ATM/ATR/p53-mediated DNA repair and promoted apoptotic signaling.

## Abstract

3-Methyladenine (3-MA) is widely recognized as a PI3K inhibitor involved in autophagy regulation. However, it is also a byproduct of DNA damage repair, and its role in modulating DNA damage response (DDR) mechanisms remains largely unexplored. Cisplatin (CDDP), a cornerstone chemotherapeutic agent for nasopharyngeal carcinoma (NPC), exerts its cytotoxic effects by inducing DNA damage in tumor cells. This study investigates the combined effects of CDDP and 3-MA on NPC cells. Cell viability and the half-maximal inhibitory concentration (IC50) were assessed using the Cell Counting Kit-8 (CCK-8) assay. Flow cytometry was employed to analyze cell cycle distribution, mitochondrial membrane potential (MMP) alterations, and apoptosis. γ-H2AX foci formation and morphological changes were examined via fluorescence microscopy, while Western blotting was used to evaluate proteins associated with the DNA damage response. The combination treatment significantly reduced cell viability and lowered the IC50 compared to CDDP alone. While both treatments induced Sub-G1 phase arrest, the combination resulted in greater MMP loss and apoptosis. Western blot analysis further revealed that 3-MA enhanced CDDP cytotoxicity by suppressing ATM/ATR/p53-mediated DNA damage repair and promoting apoptotic signaling. These findings suggest that 3-MA sensitizes NPC cells to CDDP by disrupting DNA repair processes, offering a promising therapeutic strategy.